Introduction

CJC1295 with DAC2

musclepic 2

Products Description

Part 1: Classification and Major Categories

Based on their intended use and quality standards, CJC-1295-DAC raw materials or products can be divided into three categories:

Pharmaceutical-grade research peptides: used in preclinical pharmacology studies or clinical trial raw materials that meet pharmacopoeial quality requirements, requiring high purity, controlled impurities, and traceable production batch records.

Research-grade synthetic peptides: primarily used in basic research and in vitro/animal experiments, with relatively loose purity and impurity controls, commonly found in laboratories and academic research.

Raw materials and formulation samples: available in powder form for formulation development or process optimization, with varying quality specifications, typically requiring further purification and characterization before use in human studies.

Further subdivisions can be made based on dosage form and formulation, including powdered raw materials, soluble sustained-release formulations, and complex peptide formulations.

Part 2: Chemical Structure and Physicochemical Properties

The core of CJC-1295-DAC is a polypeptide chain with secretory activity similar to native GHRH. The amino acid sequence has been engineered to enhance receptor affinity and stability. DAC fragments typically contain structural units capable of binding to plasma proteins (such as albumin) or certain affinity domains, significantly reducing the free fraction of the peptide in plasma and prolonging its systemic circulation time.

In terms of physicochemical properties, CJC-1295-DAC typically appears as a white to off-white powder or loose crystals. Its molecular weight is significantly greater than that of a single short peptide, depending on the specific sequence and the DAC linkage. The peptide's solubility in water depends on its amino acid composition and the presence of hydrochloric acid or acetate salts. It is generally soluble in deionized water, buffers, or low-percentage organic solvents, but poorly soluble in non-polar solvents at room temperature. The peptide bond makes it sensitive to acids and bases, potentially subject to hydrolysis at extreme pH levels. It is generally recommended to avoid prolonged exposure to strong light, high temperatures, or strong acid or alkaline environments to prevent degradation and denaturation.

Section 3: Appearance and Color

High-purity CJC-1295-DAC powder typically appears as a white or off-white, uniform powder with fine particles and no visible impurities. With decreasing purity or improper storage, the powder may appear light yellow or gray, which may indicate the presence of oxidation products, residual solvents, or synthetic byproducts. After dissolution, the solution should be clear, colorless, or slightly transparent, milky white. Turbidity, particles, or precipitation indicate improper formulation or storage conditions and require further characterization.

Section 4: Advantages and Potential Applications

The primary advantage of CJC-1295-DAC is its extended duration of action. Compared to short-acting GHRH analogs, the DAC modification significantly prolongs its plasma circulation time, enabling less frequent dosing and maintaining a more stable GH-stimulating effect. Potential advantages include:

Prolonged stimulation of the pituitary gland to release growth hormone, increasing IGF-1 levels, and potentially promoting protein synthesis, tissue repair, and metabolic regulation.

The extended half-life facilitates dosing and reduces the frequency of injections, facilitating long-term research and potential therapeutic applications.

More stable GH stimulation theoretically allows for a smoother hormone profile, avoiding the adverse effects of drastic peaks and troughs.

Due to the high specificity and targeted properties of peptides, they may demonstrate advantages over traditional hormone replacement therapies in certain indicators in the short term.

It should be noted that many of these advantages are currently based on early research or theoretical deductions, clinical evidence is insufficient, and individual responses vary.

Part 5: Overview of Mechanism of Action (Non-operational Description)

CJC-1295-DAC indirectly enhances growth hormone secretion in vivo by mimicking the site of action of GHRH on the hypothalamic-pituitary axis. The introduction of DAC does not alter its basic agonist properties at the GHRH receptor. However, through reversible binding to plasma proteins or delayed clearance, it prolongs the peptide's effective exposure in vivo, thereby maintaining a longer-term stimulated pituitary state, leading to more sustained GH release and IGF-1 upregulation. This mechanism differs from direct injection of growth hormone (exogenous GH), which relies on endogenous pituitary function and may therefore have limited efficacy in patients with hypopituitarism.

Part 6: Pharmacokinetics and Stability

Pharmacokinetic characteristics are influenced by individual variability, peptide sequence, DAC type, and route of administration. The overall trend is a significantly prolonged plasma half-life, with a later peak onset and a longer duration. Metabolism in vivo is primarily a combination of peptidase hydrolysis, hepatic processing, and renal clearance. Regarding stability, the peptide is most stable when frozen or refrigerated at low temperatures; freeze-thaw cycles, repeated exposure to room temperature, or strong light accelerate degradation. Protective buffer systems, preservatives, or antioxidants are often added to formulations to enhance long-term stability.

Section 7: Preparation and Formulation Considerations (High-Level Description, Non-Experimental Procedures)

Common key considerations for the preparation of CJC-1295-DAC products include rigorous raw material identification, avoiding protease contamination, maintaining a sterile environment and low-temperature processing, and monitoring for residual solvents and endotoxins. Formulation design should consider solubility, the impact of pH on stability, and the need for cold chain transportation and lyophilization to extend shelf life. All clinical-grade or experimental-grade products must undergo rigorous quality control and regulatory compliance review before entering human studies.

Section 8: Quality Control and Identity Testing

Common methods for evaluating the quality of CJC-1295-DAC include high-performance liquid chromatography (HPLC) or reversed-phase HPLC for purity and impurity profiles, mass spectrometry (MS) for molecular weight confirmation, amino acid sequence analysis or secondary structure characterization, capillary electrophoresis, and bioassays for biological activity assessment. Sterility, endotoxins, residual organic solvents, and heavy metals are also essential testing criteria for quality release. Batch-to-batch consistency and stability testing are crucial for long-term supply.

Section 9: Application Scenarios and Research Directions

The primary applications of CJC-1295-DAC in scientific research include research on the growth hormone axis, aging biology, muscle repair and regeneration, animal models of metabolic diseases, and comparative testing of novel growth hormone-stimulating strategies. Some early or small-scale clinical studies have explored its potential effects on promoting bone repair, improving body composition, or treating certain metabolic disorders, but conclusions are conflicting. Larger, randomized, controlled clinical trials are needed to verify its safety and efficacy.

Section 10: Safety and Potential Side Effects (Cautionary Note)

The use of any GH-stimulating drug carries potential risks, and CJC-1295-DAC is no exception. Reported or theoretical safety concerns include sodium and water retention, joint swelling or pain, insulin resistance or blood sugar fluctuations, local administration reactions, and endocrine system changes caused by long-term hormonal imbalance. Because CJC-1295-DAC's action depends on endogenous pituitary function, long-term pituitary stimulation may alter endogenous hormone feedback mechanisms. Furthermore, any self-administration or frequent administration without regulatory approval carries the risk of serious consequences, so research and use should be conducted within a legal and ethical framework. Providing or encouraging specific dosing regimens, dosages, or self-experimental recommendations should be avoided.

Section 11: Regulatory and Ethical Considerations

In many countries and regions, the production, distribution, and human use of synthetic peptide drugs are strictly regulated. The use of CJC-1295-DAC in clinical research or medical applications generally requires ethics committee approval and regulatory approval. Over-the-counter distribution or misuse in competitive sports also raises legal and anti-doping rule issues. Researchers and medical practitioners should adhere to local laws, regulations, research ethics guidelines, and good clinical practice when handling such substances.

Section 12: Storage and Transportation

To maintain activity and safety, CJC-1295-DAC should be stored within the cold chain or at low temperatures. The ideal storage temperature is specified on the product label, typically between 2 and 8°C or frozen. Avoid repeated freeze-thaw cycles, vigorous shaking, and prolonged exposure to high temperatures or intense light. During transportation, the product must be packaged in a refrigerated or frozen container that meets applicable regulations and undergo an integrity inspection upon delivery.

Section 13: Recommended Use and Monitoring (Not Dosing Instructions)

In the context of legitimate research or clinical trials, monitoring, including basic physical examination, complete blood count, blood glucose, lipid profiles, liver and kidney function, and endocrine markers (such as IGF-1 and GH profiles), helps assess safety and efficacy. Any abnormal findings require prompt evaluation and appropriate medical intervention. Individual attempts in non-professional settings pose significant health risks and should be discouraged, with guidance to seek professional medical advice.

Section 14: Conclusion

CJC-1295-DAC, a growth hormone-releasing peptide modified with DAC to prolong its duration of action, has attracted attention in research and some early clinical trials due to its prolonged in vivo exposure and potential portability. However, evidence regarding its long-term safety, optimal use scenarios, and clinical benefits remains limited. Research on this type of peptide should be based on rigorous scientific methods and regulatory processes to avoid human use without adequate validation and regulatory approval. For researchers and practitioners concerned about this field, paying attention to quality control, ethical compliance and safety monitoring are indispensable prerequisites for any further work.